Coagulation factor ix recombinant human clinical trials
Also written BeneFIX, BAX326, RIXUBIS and Recombinant Factor IX.
How each study uses coagulation factor ix recombinant human is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 11 Feb 1997 · Benefix · BLA 103677 (FDA, Purple Book)
- European Union
- 27 Aug 1997 · BeneFIX · EMEA/H/C/000139 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2015 | 2 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Baxalta now part of Shire (5) · Pfizer (5) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Grifols Biologicals, LLC (1)
Often tested with
Tested in the same studies.
Preventive Intervention (1)
Studies
Open first, then newest update. How each study uses coagulation factor ix recombinant human is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- RIXUBIS PMS India (RIXUBIS PMS)CompletedPhase 4Baxalta now part of ShireNCT03565237Written as RIXUBIS: On-Demand
- Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia BCompletedPhase 4PfizerNCT04286412Written as Nonacog alfa
- BAX 326 Pediatric StudyCompletedPhase 2/3Baxalta now part of ShireNCT01488994Written as BAX326
- Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B PatientsCompletedPhase 3Baxalta now part of ShireNCT01174446Written as BAX 326
- BAX 326 (rFIX) Continuation StudyCompletedPhase 3Baxalta now part of ShireNCT01286779Written as BAX 326 (Recombinant factor IX)
- BAX 326 Surgery Study in Hemophilia B PatientsCompletedPhase 3Baxalta now part of ShireNCT01507896Written as Recombinant factor IX
- Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia BCompletedPhase 2Grifols Biologicals, LLCNCT03091751Written as BeneFIX
- Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in ChinaCompletedPhase 4PfizerNCT02336178Written as Benefix
- An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia BCompletedPhase 1PfizerNCT02213250Written as BENEFIX
- Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia BCompletedPhase 3PfizerNCT01335061Written as Nonacog alfa
- Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia BCompletedPhase 3PfizerNCT00364182Written as Recombinant Coagulation Factor IX (BeneFIX)
- Study Evaluating On-Demand Treatment With BeneFIX In Chinese SubjectsCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00866606Written as Benefix
- Study Evaluating rFIX; BeneFIX in Severe Hemophilia BCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00037557Written as BeneFIX
Given beside what is tested · 2 — coagulation factor ix recombinant human is usual care or a partner of the new treatment
- Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia BCompletedPhase 3Bioverativ Therapeutics Inc.NCT01027364Written as rFIX
- Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B PatientsCompletedPhase 1ISU Abxis Co., Ltd.NCT03186677Written as BeneFIX
As the comparator · 1 — what is tested is compared with coagulation factor ix recombinant human
Codes
What other systems call coagulation factor ix recombinant human · ClinicalTrials.gg INT014618
- UNII (FDA) 382L14738LCOAGULATION FACTOR IX RECOMBINANT HUMANConfirmed FDA, Wikidata
- RxNorm 1300488Confirmed FDA, Wikidata
- Wikidata Q28852434coagulation factor ix recombinant humanConfirmed FDA, Wikidata
- NCI Thesaurus C82270Nonacog AlfaConfirmed FDA, Wikidata
- DrugBank DB00100One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 382L14738L | COAGULATION FACTOR IX RECOMBINANT HUMAN | Confirmed FDA, Wikidata |
| RxNorm | 1300488 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28852434 | coagulation factor ix recombinant human | Confirmed FDA, Wikidata |
| NCI Thesaurus | C82270 | Nonacog Alfa | Confirmed FDA, Wikidata |
| DrugBank | DB00100 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.